Meghann Ribbens

Meghann Ribbens, PhD, is a seasoned scientist with extensive experience in formulation development, analytical methods, and project management within the biotechnology and pharmaceutical sectors. Currently serving as a Senior Scientist at Ultragenyx, Meghann focuses on AAV gene therapy, leading initiatives such as the invention of innovative high-throughput tools and authoring FDA-facing reports. Previous roles include Senior Scientist positions at Synlogic, Inc. and Qtection, where Meghann contributed to the characterization of live bacterial products and the optimization of SARS-CoV-2 diagnostics, respectively. Meghann has also demonstrated leadership as Team Lead at Liberty BioSecurity, LLC, where mentoring and project development resulted in significant advancements in novel organism research. Holding a PhD in Molecular Biology from the University of Southern California and a Bachelor's in Biochemistry from UCLA, Meghann brings a strong foundation in biological sciences and extensive technical expertise.